股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 737,901,250 | RMB | | 1 | RMB | | 737,901,250 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 737,901,250 | RMB | | 1 | RMB | | 737,901,250 | ...

Group 1: Core Insights - The report highlights a positive market sentiment despite geopolitical risks, with the Dow Jones reaching a new high and signs of recovery in the manufacturing sector [2][3] - The biopharmaceutical and innovative drug sectors have shown significant gains, with several companies experiencing substantial stock price increases [3] - The report indicates a strong demand for copper, driven by applications in electric vehicles and electronics, with a projected global copper supply shortage by 2029 [9] Group 2: Company Overview - The specific company, Jinxun Resources (3636.HK), is a leading cathode copper manufacturer, ranking fifth among Chinese producers based on output in the Democratic Republic of Congo and Zambia [7] - The company is expected to produce approximately 16,000 tons and 5,000 tons of cathode copper in the Democratic Republic of Congo and Zambia, respectively, in 2024 [7] - Jinxun Resources has experienced rapid sales growth, with total sales increasing from 7,056.7 tons in 2022 to 19,868.9 tons in 2024, representing a compound annual growth rate of 67.8% [8] Group 3: Industry Status and Outlook - The global cathode copper production is projected to grow from 21.9 million tons in 2025 to 24.7 million tons by 2029, with a compound annual growth rate of 3.0% [9] - The report anticipates a continuous increase in global cathode copper consumption, expected to rise from 27.8 million tons in 2025 to 30.5 million tons by 2029, with a compound annual growth rate of 2.3% [9] - The ongoing supply-demand imbalance is expected to lead to a copper price increase, with the average price projected to rise from 749,000 RMB in 2024 to 775,000 RMB in 2025 [9] Group 4: Advantages and Opportunities - The company benefits from a strong business presence in resource-rich regions of Africa, particularly in the Democratic Republic of Congo and Zambia, which aligns with China's "going out" strategy [10] - High efficiency in raw material utilization and industry-leading technology contribute to cost control, attracting major clients [10] - The management team possesses extensive industry knowledge and experience, enhancing the company's competitive edge [10] Group 5: Use of Proceeds - Approximately 80% of the funds raised will be used to expand core operations, including enhancing production capacity and increasing cobalt hydroxide production lines [12] - About 20% will be allocated for equipment procurement and daily operations in Anhui Province, while 20% will be used for strategic acquisitions [12] - The remaining funds will support the development of a research center in Kunming and repay bank loans [12]

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 737,901,250 | RMB | | 1 | RMB | | 737,901,250 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 737,901,250 | RMB | | 1 | RMB | | 737,901,250 | ...

Group 1 - The core viewpoint is that brain-computer interfaces (BCIs) are becoming a key part of China's 14th Five-Year Plan, with strong policy support expected to accelerate industry implementation, presenting significant investment opportunities [1] - BCIs represent both medical and technological investments, with short-term applications focused on disease treatment and long-term potential to integrate with AI and robotics, potentially opening up a trillion-dollar market [1] - The report emphasizes the importance of identifying "true brain machines" that align with national policy support and real demand, highlighting China's relative global leadership in BCI technology research [1] Group 2 - From a global perspective, China's pharmaceutical industry is characterized by "innovation upgrades and supply chain resilience," with significant overseas licensing of innovative drugs expected to surpass last year's total by Q3 2025 [2] - The report outlines a focus on high-quality development in the domestic market, emphasizing policy initiatives such as procurement optimization and diversified payment systems, alongside the commercialization of innovative drugs and the safety of supply chains [3] - The report suggests that the Chinese pharmaceutical industry is gradually gaining global competitiveness, with a long-term outlook for the industry to produce large global companies, particularly in innovative drugs and medical devices [5] Group 3 - The investment outlook for 2026 remains positive, with expectations of improved global liquidity favoring the pricing of innovative assets and government policies encouraging industry innovation [5] - Key sectors to watch include innovative drugs and medical devices, with specific companies highlighted such as Heng Rui Medicine, Innovent Biologics, and Mindray Medical [5] - The report indicates a need for investors to be aware of the challenges associated with international expansion, emphasizing the importance of assessing the international competitiveness of companies' products and teams [5]

Core Insights - The Chinese CRO industry encompasses the entire drug lifecycle, including drug research services (CRO), pharmaceutical manufacturing services (CMO/CDMO), and sales services (CSO) [1][2][5] - The industry is characterized by a lack of significant upstream relationships, with some mature markets extending services to drug marketing and patent commercialization [2] Industry Overview - The CRO industry in China is segmented into three main phases: research, production, and sales, covering preclinical and clinical stages [1] - Preclinical services focus on drug discovery, compound synthesis, and formulation development, while clinical services involve clinical trials and data analysis [1] - The production phase includes various drug types, such as chemical APIs and biologics, while the sales phase centers on demand channel management for pharmaceutical companies and healthcare institutions [1] Regional Distribution - The distribution of CRO companies in China is highly concentrated in economically developed regions: Beijing (75 companies), Shanghai (59), Jiangsu (43), and Guangdong (38) [7] - These four regions account for a significant share of the total CRO enterprises, while other provinces show limited presence [7] Key Players and Performance - Major listed companies in the CRO sector include WuXi AppTec, Kanglong Chemical, Tigermed, and others [1][5] - In 2024, WuXi AppTec leads with revenue of 29.052 billion yuan, while Chengdu XianDao boasts the highest gross margin at 57.5% [12] - Other notable companies include Kanglong Chemical with 70.47 billion yuan in preclinical revenue and a gross margin of 44.92% [12] Investment Trends - Companies in the CRO sector are focusing on core business optimization, technological enhancement, and strategic collaborations [14] - Recent investments include WuXi AppTec's acquisition of stakes in various companies to strengthen its supply chain and capabilities [16] - Chengdu XianDao has partnered with the Gates Foundation for new drug development, while Kanglong Chemical is acquiring a majority stake in a biotech firm to enhance its technical platform [16]

Core Viewpoint - The medical ETF (512170) has shown significant performance, with a daily increase of over 5% and reaching a 20-day high, indicating strong market interest and potential growth in the healthcare sector [1]. Group 1: ETF Performance - The medical ETF opened high on January 6 and saw a peak increase of over 1%, with a trading volume exceeding 350 million yuan [1]. - The ETF has recorded five consecutive days of gains, reflecting a robust upward trend in the healthcare sector [1]. Group 2: Component Stocks - Brain-computer interface stocks, specifically Sanbo Brain Science and Meihua Medical, both hit the daily limit up of 20%, marking two consecutive days of gains [1]. - Conversely, the CXO sector experienced a pullback, with Tigermed seeing a decline of over 1% [1]. Group 3: Market Insights - Tesla CEO Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices in 2026, which could accelerate the commercialization of this technology [2]. - The National Medical Products Administration of China held a meeting to expedite the review and approval of related medical devices, indicating regulatory support for the industry [2]. Group 4: Industry Outlook - CITIC Securities highlighted that China's brain-computer interface technology is relatively advanced globally, which may lead to the emergence of leading companies in this field and enhance valuations in the secondary market [3]. - Zhongtai Securities noted a potential rebound in the pharmaceutical sector after four years of decline, driven by the realization of innovative drug export logic and industry recovery due to policy reforms [3].

Group 1 - The medical ETF (512170) opened high on January 6, rising over 1% and reaching a 20-day high, with real-time transaction volume exceeding 350 million yuan. The ETF recorded a daily increase of over 5%, marking five consecutive days of gains [1][5] - Brain-computer interface stocks, including Sanbo Brain Science and Meihua Medical, both hit the 20% daily limit up, achieving two consecutive boards. Conversely, the CXO sector saw a pullback, with Tigermed falling over 1% [1][5] Group 2 - On January 5, 2026, Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices, advancing the commercialization of the technology. Concurrently, the National Medical Products Administration held a meeting to expedite the review and approval of related medical devices [3][6] - According to CITIC Securities, China's brain-computer interface technology is relatively advanced globally, with potential to cultivate leading companies in the sector. This could enhance the valuations of related listed companies in the secondary market and stimulate financing in the primary market, creating a synergy between capital and industry development [7] - Zhongtai Securities noted that the pharmaceutical sector is expected to rebound in 2025 after four consecutive years of decline, driven by the realization of innovative drug export logic and industry recovery post-policy reform. Certain areas of the medical device sector may also see a reversal of difficulties [7]

Group 1: Market Overview - The international oil market is experiencing volatility due to uncertainty surrounding Venezuela's oil reserves, with WTI crude oil rising by 1.64% to $58.15 per barrel and Brent crude oil increasing by 1.61% to $61.71 per barrel [4] - Major European stock indices closed higher, with the UK FTSE 100 up by 0.54%, Germany's DAX up by 1.34%, and the Euro Stoxx 50 up by 1.25% [4] - US stock indices also saw gains, with the Dow Jones rising by 1.23% to a new high, the S&P 500 up by 0.64%, and the Nasdaq up by 0.69% [4] Group 2: Commodity Performance - Spot gold increased by 2.74% to $4,449.04 per ounce, while spot silver rose by 5.42% to $76.6 per ounce [7] - LME copper prices surged to $13,000 for the first time [3] - The performance of precious metals is attributed to increased safe-haven demand amid the situation in Venezuela [3] Group 3: Specific Company Movements - Chevron (CVX.N) shares rose by 5.2%, nearing a new high, while Tesla (TSLA.O) increased by 3% [4] - In the Hong Kong market, Kuaishou (01024.HK) surged over 11%, and Bilibili (09626.HK) rose over 5% [5] - In the A-share market, insurance stocks performed strongly, with New China Life Insurance rising over 8% to reach a historical high [6]

Summary of Tigermed (3347.HK) Conference Call Company Overview - **Company**: Tigermed (3347.HK) - **Market Cap**: HK$51,795 million (approximately US$6,654 million) [2] Industry Insights - **Industry**: Innovative drugs financing in China - **Growth Metrics**: - Total financing size for innovative drugs in China increased by 342% year-over-year (yoy) to Rmb18.0 billion in December 2025, marking a new high in the past three years [1] - Primary market financing for innovative drugs grew by 140% yoy to US$1.1 billion in December 2025 [1] - For the year 2025, total financing and primary market financing sizes rose by 38% and 25% yoy, respectively [1] Financial Performance and Projections - **Booking Growth**: Tigermed is expected to deliver higher new booking growth in 2026 compared to a mid-teens percentage in 2025 [1] Valuation - **Target Price**: HK$73.00, representing a potential upside of 72.0% from the current price of HK$42.44 [2] - **Expected Total Return**: 72.8%, including a dividend yield of 0.8% [2] - **Valuation Breakdown**: - HK$21.8 per share for clinical trial solutions - HK$35.8 per share for clinical-related and laboratory services - HK$0.4 per share for other services - HK$1.5 per share for net cash - HK$13.5 per share for investment income [11] Risks - **Downside Risks**: - Weaker-than-expected client orders - Intense market competition - Less-than-expected investment gains - Increased investment in AI potentially affecting operating profit margin (OPM) - Margin pressure due to overseas expansion - Lower-than-expected long-term margins with AI adoption [12] Conclusion - Tigermed is positioned to benefit from the significant growth in the innovative drugs financing sector in China, with strong projections for new bookings and a favorable valuation outlook. However, potential risks related to market dynamics and operational challenges must be monitored closely.

Summary of Key Points from the Conference Call Industry Overview - The pharmaceutical sector is currently in a left-side layout phase after adjustments in 2025, with both institutional holdings and valuations positioned for upward elasticity, particularly in innovative drugs and their supply chains for 2026, benefiting from China's strengthening innovation competitiveness [1][4] - The recovery of the innovative industry chain is expected to continue, with CDMO orders and performance starting to recover from 2024, further improving in 2025 and expected to sustain into 2026 [1][9] Core Insights and Arguments - The driving forces behind the enhancement of China's innovation competitiveness include the successful implementation of business development (BD), overseas clinical progress, and commercialization, along with breakthroughs in new technologies such as XDC, dual antibodies, and small nucleic acids [5] - Investment opportunities in 2026 are concentrated in globally competitive assets, including innovative drugs, high-end manufacturing, and domestic demand-related sectors, particularly those with recovery logic [2] - The domestic demand recovery trend is clear, strengthening quarter by quarter in 2025, driven by high domestic innovation BD, a warming primary and secondary market, and an increase in IPOs in both A-shares and Hong Kong stocks [20] Notable Companies and Technologies - Key companies to watch include Innovent Biologics, Botai Biological Products, and Engen Biologics, which are core recommended assets due to their potential for significant data readouts and BD catalysts [6][10] - In the CRO sector, companies like Tigermed and Zhaoyan New Drug are expected to see performance turning points in 2026, supported by a recovery in domestic demand [3][21] - The CDMO sector is projected to continue its growth trajectory, with leading companies such as WuXi AppTec and Kelun Biotech expected to perform well due to increasing orders from overseas [22][23] Emerging Technologies and Investment Opportunities - Emerging technologies such as brain-computer interfaces and AI in pharmaceuticals are anticipated to bring new investment opportunities, with potential IPOs in these areas [12][29] - The central OTC sector is expected to see marginal recovery in 2026, with key companies like China Resources and Dong'e Ejiao being highlighted for their potential growth [13][30] Upcoming Catalysts and Key Events - Important upcoming events include the JPMorgan conference, which may provide data updates and BD changes, and significant data readouts expected in Q1 and April from major conferences [8][10] - The performance of companies in the first quarter of 2026 is anticipated to show significant elasticity and fundamental support, particularly in the CRO and innovative drug sectors [11][20] Conclusion - The pharmaceutical industry is positioned for a recovery phase with significant investment opportunities in innovative drugs, CDMO, and CRO sectors, driven by domestic demand recovery and technological advancements. Key companies and upcoming events will play a crucial role in shaping the market dynamics in 2026 [1][2][4][20]